RxDoctor Payments Data

Mohamad Sankari, MD

Gastroenterology · Charleston, WVNPI 1043274830

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.7% of the total across 65 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 21.7% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for gastroenterology clinicians in WV, where the typical reported total is $1,371.

$1,299in general payments, 2019–2025

Across 65 payments — averaging $19.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$282
  • AbbVie$252
  • Johnson & Johnson$181
  • Takeda Pharmaceuticals U.S.A., Inc.$131
  • GSK$104
  • Pfizer$59
  • plus $291 from 11 others

What the payments were for

  • Food & beverage$1,27098%
  • Gifts$292%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,299 in reported general payments places this provider in the 45th percentile of 72 gastroenterology providers in West Virginia.

See all gastroenterology providers in West Virginia

Medicare billing

Part B allowed, 2024
$117,530
Medicare patients
474
Services billed
947

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab23$579,439
CreonLipase/Protease/Amylase100$353,127
ZenpepLipase/Protease/Amylase51$185,766
XifaxanRifaximin40$122,979
Cimzia (2 Pack)Certolizumab Pegol13$64,993
LinzessLinaclotide28$25,170
Mesalamine34$11,305
Mesalamine ErMesalamine31$7,982
Budesonide DrBudesonide18$4,753
MovantikNaloxegol Oxalate11$4,652
Ursodiol19$3,400
Pantoprazole Sodium320$3,272
Budesonide EcBudesonide26$3,021
Colestipol Hcl12$1,781
Omeprazole124$995

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$181$579,43923 claims
AbbVieCreon, Linzess$252$378,297128 claims
Aimmune Therapeutics, Inc.Zenpep$37$185,76651 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$35$122,97940 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 72 gastroenterology providers in West Virginia.

Other gastroenterology in Charleston

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →